Insights
Nov 3, 2026·KnightByrd Tech LLC·5 min read

Regulatory Claim Substantiation Standards and FTC Penalty Offense Risks for Consumer Health Brands

An analysis of the FTC standard for competent and reliable scientific evidence, three common claim substantiation traps, and civil penalties under 15 U.S.C. § 45(m)(1)(B).

Share the signal

If you market a supplement, a functional beverage, a topical cosmetic, or an over-the-counter wellness product, your growth depends on claims. You tell the consumer that a compound sharpens focus, soothes inflammation, accelerates recovery, or clears skin.

To back that up, your marketing deck probably links to a folder of clinical studies. Your regulatory affairs team has reviewed the ingredient supplier’s white paper. Everyone feels protected.

They usually aren't.

There is a vast, expensive gulf between what consumer brands consider "science" and what regulatory bodies legally define as "competent and reliable scientific evidence." Crossing that line is surprisingly easy, particularly when internal teams confuse scientific plausibility with regulatory substantiation.

(A brief note before we unpack the standard: this analysis is for informational purposes only and does not constitute legal advice.)

The Legal Term of Art

The phrase "competent and reliable scientific evidence" is not marketing shorthand. It is an evidentiary standard.

The Federal Trade Commission defines it as tests, analyses, research, or studies that have been conducted and evaluated in an objective manner by qualified individuals, using procedures generally accepted in the profession to yield accurate and reliable results. The agency outlines these parameters in detail in its Health Products Compliance Guidance.

When regulators evaluate whether a claim holds up, they do not ask whether an ingredient has an interesting biochemical mechanism. They ask whether the specific claim you make to a consumer matches the rigorous parameters of the underlying data.

In our experience auditing claim documentation, brands almost never set out to deceive consumers. Instead, they fall into three distinct cognitive traps regarding their own evidence:

1. The "borrowed science" trap. An ingredient supplier conducts a double-blind, placebo-controlled trial on a trademarked botanical extract using a 500mg daily dosage. A brand formulates a capsule with 50mg of generic root powder, then cites the supplier’s human clinical trial on their product page. The science is real; the brand’s substantiation is non-existent.

2. The mechanism-as-outcome trap. A petri dish or rodent study demonstrates that an active polyphenol reduces oxidative markers in isolated cells. The marketing team translates this into: "Protects your body from cellular damage." In the eyes of the law, in vitro assays and animal models cannot substantiate health outcomes in living humans unless reliable, validated translation can be demonstrated.

3. The statistical vs. clinical trap. A study shows a 4% improvement in a symptom score that achieves statistical significance ($p < 0.05$). A brand markets this as "dramatic relief." A statistically detectable movement in a lab questionnaire rarely equates to a tangible, clinically meaningful real-world benefit.

The Uncomfortable Reality of Product Substantiation

Here is what most compliance guides will not tell you: the wellness and consumer health sector has built a multi-billion-dollar marketing engine on top of citation theater.

Founders and marketing leads frequently treat scientific studies like visual garnishes—footnotes to satisfy a retailer or an ad platform—rather than strict boundaries that govern what words may exit a copywriter’s keyboard. The prevailing assumption is that as long as a relevant paper exists on PubMed, the claim is covered.

It isn't. If your marketing implies that your finished product delivers a specific health outcome, you are legally responsible for substantiating that exact outcome for that formulation, at that dose, for that target population. Regulators do not grade on a curve because a brand is early-stage or operating on thin margins.

Why the Stakes Just Shifted

Historically, many brands treated claim substantiation as a low-probability risk. The FTC typically pursued egregious fraud or issued warning letters that required basic website revisions.

That operational reality has changed under the Commission's revived Penalty Offense Authority. Under 15 U.S.C. § 45(m)(1)(B), if the FTC provides a company with formal notice that specific commercial conduct is deceptive or unlawful, subsequent violations expose the business to civil penalties of up to $50,120 per violation.

To establish this liability, the Commission mailed formal Notices of Penalty Offenses to thousands of corporate entities.

Across five published recipient lists, our index tracks 2,527 distinct companies. Fifty of those organizations received letters across more than one category. The breakdown of those notices covers:

  • Money-making opportunities: 1,131 companies
  • Endorsements and testimonials: 705 companies
  • Substantiation of product claims: 665 companies
  • For-profit education: 70 companies
  • Misuse of information collected in confidential contexts: 6 companies

To be entirely clear: appearing on an FTC recipient list is not an indication that a company has engaged in wrongdoing or violated the law.

Receiving a notice simply means the Commission wrote to the company to establish "actual knowledge" of conduct the agency considers unfair or deceptive under administrative law. It puts the company on official notice that engaging in that conduct moving forward triggers direct financial exposure.

For the 665 companies that received the notice targeting product substantiation, the threshold for what constitutes adequate evidence is no longer an academic debate. It is a potential $50,120 calculation per infraction.

Know Your Standing

If your company manufactures or markets consumer health products, your first audit should not be your ad account—it should be your evidence dossier. Match the precise wording of your high-conversion claims against the actual dosage, formulation, and clinical design of your source material. If the studies do not mirror what you sell, your claims are exposed.

You should also confirm whether your organization is already on the Commission’s radar. Because the FTC published these distribution rosters across five disparate, unindexed PDF files, verifying whether your brand received formal notice used to require manual searching through thousands of entries. We built a consolidated, free searchable index of all 2,527 recipient records across all five lists so founders, legal counsel, and compliance teams can check their corporate status in a few seconds.


::: cta Look your own company up. The FTC published five Notice of Penalty Offenses recipient lists as five separate PDFs. We made all of them searchable in one place — 2,527 companies, free, no account. Appearing on a list is not an indication that a company has done anything wrong.

How we read claims against evidence, including the limits of the method, is published in full.

And the question the list raises next: what do your own published pages claim today, and what evidence sits beside each claim? We will read your pages and send back the inventory, free — every claim found, and which of them would face a substantiation question if somebody asked. It is a reading, not a verdict, and it is not legal advice. :::

FTCClaim SubstantiationHealth Products Compliance GuidanceCompetent and Reliable Scientific EvidencePenalty Offense Authority
This is live demand. Cast your vote on the Nexus Pulse board.
Share the signal